GenSight Biologics launches a reserved offering of c. €25 million by means of an accelerated bookbuilding process

GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021

GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs

GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non Human Primates

GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update

GenSight Biologics Announces its 2021 Financial Calendar

GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®

GenSight Biologics announces the partial conversion of convertible bonds and full exercise of share warrants by Kreos Capital

GenSight Biologics Announces Publication of Results from LUMEVOQ® REVERSE Pivotal Phase III Trial and Non-Human Primate Study in Science Translational Medicine

Article – EN